By MATTHEW HOLT Strap in for the tale of why your hero is spending most of his life down YouTube rabbit holes of cardiology videos while blund...
By EMANUEL SARKEES The United States is in the middle of what researchers are calling one of the most significant pharmacological developments...
By GEORGE BEAUREGARD Back in the late 90s to early 2000s, I had a robust (independent) internal medicine practice. These were the days before...
By JOHN SAMARAS Eli Lilly sells a month of 10mg Zepbound for $449 through LillyDirect, its own pharmacy. That price holds only if you refill w...
By KIM BELLARD One of the key “cost savings” in last years’ Big, Beautiful Bill were work requirements imposed on most working aged beneficiar...
By STEVEN ZECOLA Congress will need to amend its faltering Parkinson’s disease legislation if it hopes to achieve meaningful results. Why Ch...
By DEEKSHA HEGDE How to spot a fundamental business model shift from a mile away, long before the PR calls it a product launch or market expan...
By MIKE MAGEE Two decades ago, I was heavily into health visioning. I learned quickly that it was relatively easy to predict what would happen...